Sansheng Pharmaceutical antifygal drug Ampholipad tablets market application was accepted by China's State Drug Administration.

Introduction: Ampholipad (TM) registration application has been accepted by the National Drug Administration Drug Review Center (CDE).
August 26, Sansheng Pharmaceuticals and its partner, Taiwan Microlipids Co., Ltd., announced that TLC's Ampholipad (TM) registration application had been accepted by the National Drug Administration's Drug Review Center (CDE), a chemical generic of Gilead Inc.'s AmBisome (R) for the treatment of systemic fungal infections.
Chinese mainland market is currently without AmBisome ® or its generic products on the market.
Ampholipad ™ been approved for sale in Taiwan for many years and has recently been approved to expand production to exceed one million units per year.
TLC has authorized partner Sansheng Pharmaceuticals to be responsible for the commercialization ™ ampholipad Chinese mainland in the world.
Sansheng Pharmaceuticals is a comprehensive biopharmaceutical enterprises, with high market share and strong marketing strength.
2019, Sansheng Pharmaceuticals' operating income exceeded RMB5.3 billion (approximately US$750 million).
agreement, TLC will receive a milestone payment for this drug registration application.
.